Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early viscoelastometric guided fibrinogen replacement combined with escalation of clinical care reduces progression in postpartum haemorrhage: a comparison of outcomes from two prospective observational studies.

International journal of obstetric anesthesia·2024
Same author

A description of the coagulopathy characteristics in amniotic fluid embolism: a case report.

International journal of obstetric anesthesia·2022
Same author

Corrigendum to "The incidence, aetiology, and coagulation management of massive postpartum haemorrhage: a two-year national prospective cohort study" [Int J Obstet Anesth. 2021;47:102983].

International journal of obstetric anesthesia·2022
Same author

Comparison of haematological indices and transfusion management in severe and massive postpartum haemorrhage: analysis of a two-year national prospective observational study.

International journal of obstetric anesthesia·2022
Same author

The sensitivity and specificity of rotational thromboelastometry (ROTEM) to detect coagulopathy during moderate and severe postpartum haemorrhage: a prospective observational study.

International journal of obstetric anesthesia·2021
Same author

Utility of viscoelastography with TEG 6s to direct management of haemostasis during obstetric haemorrhage: a prospective observational study.

International journal of obstetric anesthesia·2021
Same journal

Clinical Factors for Predicting Synovial Hypertrophy in Early Haemophilic Arthropathy on Prophylaxis: A Cross-Sectional Study of Patient- and Joint-Level Analyses Using Musculoskeletal Ultrasound.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Utilisation and Perceived Value of Genetic Counsellors Within US Haemophilia Treatment Centres.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Correction to "Reference Values for the Haemophilia Joint Health Score in Patients With Severe Haemophilia Derived From the Canadian Bleeding Disorder Registry".

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Monitoring of Coagulation Potential of Efanesoctocog Alfa in Haemophilia A: Insights From Conventional and Global Hemostasis Assays.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Perceived Barriers to Healthcare Access Among Paediatric Patients With Haemophilia in Cambodia: A Cross-Sectional Survey.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH-AHA-EMI Study.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
See all related articles

Related Experiment Video

Updated: May 21, 2026

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

Personalized prophylaxis.

P W Collins1

  • 1Arthur Bloom Haemophilia Centre, School of Medicine, Cardiff University, Heath Park, Cardiff, UK. peter.collins@.wales.nhs.uk

Haemophilia : the Official Journal of the World Federation of Hemophilia
|June 26, 2012
PubMed
Summary
This summary is machine-generated.

Personalized prophylaxis is the recommended treatment for severe haemophilia, considering individual factors like bleeding patterns and activity levels. Optimizing treatment regimens improves outcomes and access to care.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Related Experiment Videos

Last Updated: May 21, 2026

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Area of Science:

  • Haematology
  • Pharmacokinetics
  • Medical Treatment

Background:

  • Severe haemophilia necessitates prophylactic treatment for optimal patient outcomes.
  • Current prophylactic regimens may not be universally optimal, highlighting the need for individualized approaches.
  • Factor VIII pharmacokinetics play a crucial role in tailoring treatment strategies.

Purpose of the Study:

  • To emphasize the importance of personalized prophylaxis in severe haemophilia management.
  • To explore the factors influencing the optimization of individual prophylactic regimens.
  • To discuss the cost-effectiveness and future directions of haemophilia prophylaxis.

Main Methods:

  • Personalized regimen planning based on bleeding patterns, musculoskeletal health, physical activity, and factor levels.
  • Measurement of factor VIII pharmacokinetics using routine clinical methods and computer analysis.
  • Consideration of changing individual circumstances and age-related pharmacokinetic variations.

Main Results:

  • Individualized prophylaxis, considering multiple patient-specific factors, is superior to a one-size-fits-all approach.
  • Factor VIII pharmacokinetics can be readily measured and utilized for treatment personalization.
  • Optimizing prophylaxis frequency can enhance cost-effectiveness and treatment access.

Conclusions:

  • Personalized prophylaxis is the optimal therapy for severe haemophilia, requiring ongoing adjustments.
  • Integrating pharmacokinetic data with clinical factors is key to effective treatment individualization.
  • Improving cost-effectiveness and accessibility of prophylaxis are critical future goals for severe haemophilia care.